Atectura Breezhaler (indacaterol/mometasone furoate) / Merck (MSD), Novartis, Valeo Pharma  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Atectura Breezhaler (indacaterol/mometasone furoate) / Novartis, Merck (MSD)
NCT06067100: U-LABA/ICS Effects on Exercise Performance, Indacaterol

Recruiting
N/A
30
Europe
Indacaterol and Mometasonefluroate (low dose), Placebo, Indacaterol and Mometasonefluroate (high dose)
Morten Hostrup, PhD
Exercise Performance
09/25
12/25
NCT06077019: Role of Lung Function for Exercise Capacity in Well-trained Individuals

Recruiting
N/A
60
Europe
Vilanterol and Fluticasone Furoate, Indacaterol and Mometasone Furoate, Placebo
Morten Hostrup, PhD
Exercise Performance
09/25
12/25
NCT05217810: A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®

Recruiting
N/A
600
RoW
Atectura inhalation capsule (150/80ug), Atectura inhalation capsule (150/160ug), Atectura inhalation capsule (150/320ug)
Novartis Pharmaceuticals
Asthma
12/26
12/26

Download Options